Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical TechnologyBoehringer Ingelheim has received Japan's MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF. Respiratory Read full story Post navigation Previous: Another LAG-3 setback as Regeneron drug fails phase 3 trialNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
